ProQR Therapeutics

About:

ProQR Therapeutics is a biotech company focused on developments of drugs to treat genetic disorders.

Top Investors: Eli Lilly, Sofinnova Partners, Pontifax, Rett Syndrome Research Trust

Description:

ProQR Therapeutics is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa. The company's main product candidates are QR-010, QR-110, and QR-313. Its product pipeline includes QRX-704, QRX-504, QRX-421, QRX-323 etc.

Total Funding Amount:

$434M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Leiden, Zuid-Holland, The Netherlands

Founded Date:

2012-01-01

Contact Email:

info(AT)proqr.com

Founders:

Daniel A. de Boer, Dinko Valerio, Gerard Platenburg